EP Patent

EP1240899A2 — Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections

Assigned to Valeant Research and Development · Expires 2002-09-18 · 24y expired

What this patent protects

Ribavirin® is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin® is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. In other apsects of the inven…

USPTO Abstract

Ribavirin® is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin® is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. In other apsects of the invention, one or more Ribavirin® analogs are administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. The Ribavirin® analog(s) may be used to suppress or enhance Th1 or Th2-mediated T cell responses.

Drugs covered by this patent

Patent Metadata

Patent number
EP1240899A2
Jurisdiction
EP
Classification
—
Expires
2002-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Valeant Research and Development
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.